- Home
- WSR vs CRGX Comparison
WSR vs CRGX Comparison
Compare WSR & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSR
- CRGX
- Stock Information
- Founded
- WSR 1998
- CRGX 2021
- Country
- WSR United States
- CRGX United States
- Employees
- WSR N/A
- CRGX N/A
- Industry
- WSR Real Estate Investment Trusts
- CRGX
- Sector
- WSR Real Estate
- CRGX
- Exchange
- WSR Nasdaq
- CRGX Nasdaq
- Market Cap
- WSR 674.6M
- CRGX 621.4M
- IPO Year
- WSR 2010
- CRGX 2023
- Fundamental
- Price
- WSR $13.40
- CRGX $12.39
- Analyst Decision
- WSR Strong Buy
- CRGX Strong Buy
- Analyst Count
- WSR 3
- CRGX 6
- Target Price
- WSR $15.67
- CRGX $31.80
- AVG Volume (30 Days)
- WSR 219.1K
- CRGX 287.3K
- Earning Date
- WSR 03-03-2025
- CRGX 11-12-2024
- Dividend Yield
- WSR 4.03%
- CRGX N/A
- EPS Growth
- WSR N/A
- CRGX N/A
- EPS
- WSR 0.41
- CRGX N/A
- Revenue
- WSR $149,446,000.00
- CRGX N/A
- Revenue This Year
- WSR N/A
- CRGX N/A
- Revenue Next Year
- WSR $4.48
- CRGX N/A
- P/E Ratio
- WSR $32.65
- CRGX N/A
- Revenue Growth
- WSR 4.67
- CRGX N/A
- 52 Week Low
- WSR $10.77
- CRGX $10.91
- 52 Week High
- WSR $15.36
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- WSR 37.69
- CRGX 39.66
- Support Level
- WSR $13.05
- CRGX $10.91
- Resistance Level
- WSR $13.64
- CRGX $15.75
- Average True Range (ATR)
- WSR 0.28
- CRGX 1.20
- MACD
- WSR -0.05
- CRGX -0.11
- Stochastic Oscillator
- WSR 28.00
- CRGX 30.08
About WSR Whitestone REIT
Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. Its property portfolio includes retail and office/flex properties. The company's properties are located in business-friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The organization derives revenue in the form of rental revenues.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.